Pyxis Oncology (NASDAQ:PYXS) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS

Pyxis Oncology (NASDAQ:PYXS) posted its quarterly earnings results on Thursday. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02), Zacks reports.

Pyxis Oncology Price Performance

Shares of NASDAQ:PYXS traded up $0.07 during mid-day trading on Friday, reaching $2.28. 986,489 shares of the company traded hands, compared to its average volume of 619,030. The company’s 50 day moving average price is $1.72 and its 200-day moving average price is $2.30. The firm has a market cap of $143.31 million, a PE ratio of -1.74 and a beta of 1.43. Pyxis Oncology has a 52 week low of $0.97 and a 52 week high of $5.55.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Bank of America Corp DE boosted its stake in Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares during the period. Acadian Asset Management LLC bought a new position in shares of Pyxis Oncology during the first quarter worth $81,000. XTX Topco Ltd purchased a new position in Pyxis Oncology during the second quarter valued at $40,000. Marshall Wace LLP purchased a new stake in Pyxis Oncology in the 2nd quarter worth $163,000. Finally, Qube Research & Technologies Ltd increased its holdings in shares of Pyxis Oncology by 128.4% in the second quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock worth $113,000 after purchasing an additional 57,935 shares during the last quarter. Hedge funds and other institutional investors own 39.07% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PYXS shares. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Pyxis Oncology in a report on Tuesday, March 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Stifel Nicolaus cut their price objective on Pyxis Oncology from $9.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday, March 24th. Wedbush initiated coverage on Pyxis Oncology in a research report on Tuesday, May 5th. They issued an “outperform” rating and a $6.00 target price on the stock. Finally, Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a report on Saturday. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Pyxis Oncology has an average rating of “Moderate Buy” and an average target price of $6.83.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.